Susceptibility of ICU and Non-ICU Ward Subsets of Lower Respiratory Tract Infection Isolates of Pseudomonas aeruginosa and Enterobacterales to C/T and Comparator Agents

Susceptibility of ICU and Non-ICU Ward Subsets of Lower Respiratory Tract Infection Isolates of Pseudomonas aeruginosa and Enterobacterales to C/T and Comparator Agents ^a—SMART 2018-2019, United States

Species/ward type	N	% Susceptible										% MDR
Species/ward type	N	C/T	P/T	FEP	CAZ	CRO	ATM	MEM	IMI	LVX	AMK
P. aeruginosa
ICU	495	96.0	72.3	78.0	76.7	NA	68.1	72.9	64.4	66.7	96.2	17.8
Non-ICU	583	96.7	79.4	83.0	82.9	NA	72.2	79.8	69.0	61.9	96.6	10.5
Enterobacterales
ICU	1005	91.3	87.4	89.4	83.2	80.5	83.3	97.5	87.5	81.7	99.0	13.0
Non-ICU	726	92.6	89.3	89.4	83.3	79.6	85.1	98.5	85.1	83.0	98.6	11.7
P. aeruginosa + Enterobacterales
ICU	1500	92.9	82.4	85.6	81.0	NA	78.3	89.4	79.9	76.7	98.1	14.6
Non-ICU	1309	94.4	84.9	86.6	83.1	NA	79.4	90.1	77.9	73.6	97.7	11.2

AMK, amikacin; ATM, aztreonam; C/T, ceftolozane/tazobactam; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; ICU, intensive care unit; IMI, imipenem; LVX, levofloxacin; MEM, meropenem; NA, not available; P/T, piperacillin/tazobactam.

^aStatistically significant differences between intensive care unit (ICU) and non-ICU are shown in bold font.

section name header

Table 12-3